PT-141 is a research-grade melanocortin peptide supplied strictly for in-vitro and laboratory research use only. It is not for human or animal consumption, is not a dietary supplement, is not a cosmetic, and is not an FDA-approved drug. This profile is third-person science education describing what PT-141 is and what researchers measure when they study it in cell-culture and animal-model systems. Nothing here is medical or dosing guidance, and nothing implies any reader should acquire or use the compound.
What PT-141 Is
PT-141, known in the research literature by the developmental name bremelanotide, is a synthetic melanocortin peptide studied as a molecular tool in receptor pharmacology and neuroscience research. It belongs to the melanocortin analog family, a group of compounds derived from the natural signaling peptide alpha-MSH. In laboratory contexts PT-141 is used to probe how melanocortin receptors respond to a cyclic, enzymatically stable ligand. It is a research-use-only reference material, not a product intended for people or animals. For foundational background on peptide structure, see what peptides are.
The compound is most often discussed in connection with central melanocortin signaling, and in particular with the MC4R receptor subtype that is expressed in the brain. This central emphasis is what distinguishes PT-141 within the melanocortin analog family, and it is the reason the compound appears frequently in neuroscience-oriented receptor studies rather than in pigment-biology work alone. Everything described here is a matter of receptor pharmacology in cells and animal models.
PT-141 sits alongside related melanocortin analogs such as Melanotan II in the broader research picture, and the receptor map that connects these compounds is laid out in the melanocortin system research guide. The product-level overview for this compound lives at the PT-141 research reference. This profile focuses specifically on PT-141 as a named research chemical, describing its chemistry, the receptors it engages in cell studies, and the documentation that lets a laboratory trust the material it receives.
Structure and Melanocortin Lineage
In structural terms, PT-141 is a cyclic melanocortin peptide built around the conserved message sequence that defines this family. All melanocortin ligands, natural and synthetic, share a core motif often summarized as His-Phe-Arg-Trp (the HFRW pharmacophore), and receptor engagement across the family depends on this shared segment. PT-141 presents that motif on a cyclic backbone that resists rapid enzymatic breakdown, which is why it serves as a stable and reproducible tool in receptor assays.
PT-141 is related in its development history to the cyclic analog Melanotan II, and the research literature describes it as arising from that broader lineage of stabilized melanocortin chemistry. The cyclization strategy that gives Melanotan II its enzymatic stability is the same general approach that underlies PT-141, though the two compounds are characterized by different receptor emphases. The following features summarize the structural profile investigators reference:
- A cyclic peptide architecture that constrains the active conformation and improves stability relative to the linear natural peptide alpha-MSH.
- The conserved His-Phe-Arg-Trp message segment shared across the melanocortin family, which mediates receptor binding.
- A developmental relationship to the cyclic analog class exemplified by Melanotan II, placing PT-141 in the same stabilized-chemistry lineage.
- A receptor emphasis, discussed below, that leans toward central melanocortin subtypes rather than the pigment-associated MC1R alone.
Receptor Pharmacology: A Central Melanocortin Emphasis
The melanocortin receptor family comprises five G-protein-coupled receptors, designated MC1R through MC5R, each coupling to the Gs pathway and driving accumulation of the second messenger cyclic AMP (cAMP) when activated. Different melanocortin ligands are characterized by which subtypes they engage most strongly. In cloned-receptor studies, PT-141 is described as a melanocortin agonist whose profile includes engagement of central subtypes, with MC4R among the receptors of principal research interest.
MC4R is expressed in the hypothalamus and connected brain regions, where in animal models it sits within circuitry that integrates a range of neuroendocrine signals. This central expression is why PT-141 is studied in a neuroscience context rather than only in pigment-cell biology, distinguishing it from the more MC1R-leaning linear analog Melanotan I. Researchers use PT-141 to ask how a stable agonist interacts with these central receptors in controlled cell and animal-model systems. The receptor points most often referenced are:
- MC1R, most associated with pigment-cell biology and studied more heavily with linear analogs.
- MC3R and MC4R, the central subtypes tied in animal models to hypothalamic circuitry, with MC4R a principal focus for PT-141.
- MC5R, associated in the literature with exocrine-gland biology, included in subtype comparison panels.
- A shared Gs-cAMP signaling readout, which lets investigators compare PT-141 against reference agonists across the whole receptor panel.
Mechanisms Studied in Preclinical and In-Vitro Models
Research on PT-141 spans two broad levels: the molecular level, where investigators measure how the compound binds and activates individual receptors, and the systems level, where animal-model studies examine how central melanocortin circuits respond. Both levels are strictly preclinical. The compound is a probe for characterizing receptor and circuit behavior in non-human systems.
Nothing in this literature describes an effect in a person, and observations in simplified cell systems or animal models do not transfer to humans. PT-141 is referenced here only as a laboratory research material used to generate mechanistic data. For questions that touch human health, a licensed clinician is the appropriate source, not a research-chemical profile.
Central Nervous System Pathway Models
In neuroscience research, PT-141 has been examined in animal models as a tool for probing central melanocortin pathways, which are distinct from the peripheral vascular signaling studied with unrelated classes of compounds. Investigators using rodent models look at how activation of central melanocortin receptors correlates with measurable neural and behavioral endpoints defined by their protocols. These are model-system observations reported in the animal literature and are not statements about human physiology.
This central mechanism is the feature that situates PT-141 within neuroendocrine research rather than pigment biology. The distinction between central melanocortin circuitry and peripheral pathways is one reason the compound is studied as a mechanistically informative reference, and it is developed further in the melanocortin system research guide.
Receptor-Signaling and Binding Assays
At the molecular level, PT-141 is characterized in cloned-receptor systems using standard pharmacology assays. Binding studies estimate the affinity of the compound for each melanocortin subtype, while functional assays measure cAMP accumulation as a readout of Gs-coupled receptor activation. Running these assays across the MC1R through MC5R panel lets investigators build a selectivity profile and compare PT-141 against reference agonists.
These in-vitro measurements are the backbone of melanocortin pharmacology. They describe how the molecule behaves at the receptor level under defined laboratory conditions, using purified or cell-expressed receptors. Such data characterize the compound as a research reagent and carry no implication for use in humans or animals.
Handling, Solubility, and Stability
In research settings, PT-141 is typically supplied as a lyophilized (freeze-dried) solid. Laboratory reconstitution generally uses a suitable sterile solvent, often bacteriostatic or sterile water, added slowly against the vial wall so the peptide dissolves without unnecessary agitation. The concentration prepared depends entirely on the design of a given experiment. These are standard peptide-handling notes for laboratory work, not instructions for any use in people or animals.
Sealed lyophilized vials are usually stored frozen and protected from light and moisture, while reconstituted solutions are generally kept refrigerated and used within a limited window to preserve integrity. Repeated freeze-thaw cycles are typically avoided. Handling should follow the supplier documentation and the researcher's institutional practices. The cyclic structure of PT-141 contributes to its relative stability, but proper storage remains important for reproducible results.
What Researchers Measure
When PT-141 is used as a reference compound, the measurements investigators report cluster around receptor pharmacology and material quality. Typical endpoints include:
- Receptor binding affinity, estimating how tightly PT-141 associates with each melanocortin subtype in a cloned-receptor system.
- Functional potency, measured as cAMP accumulation that reflects Gs-coupled receptor activation.
- Subtype selectivity, comparing responses across MC1R through MC5R to define the compound's receptor profile.
- Peptide stability, tracking how the material holds up under defined storage and reconstitution conditions.
- Identity and purity of the supplied lot, confirmed by analytical testing before the material is used in any experiment.
Why Purity and a Certificate of Analysis Matter
In peptide research, a measurement is only as reliable as the compound behind it. A cyclic peptide like PT-141 can be confounded by truncated sequences, incomplete cyclization, or residual synthesis byproducts, any of which can distort receptor data and make an experiment impossible to reproduce. Documenting exactly what a vial contains is therefore a scientific requirement, not a formality.
A Certificate of Analysis (COA) documents what analytical testing confirmed for a specific lot. A meaningful COA reports identity, typically by mass spectrometry, and purity, typically by high-performance liquid chromatography (HPLC) expressed as a main-peak percentage, and it ties those results to a lot number that matches the physical vial. Peptides Factory Direct documents identity and purity for its research-use-only catalog; to review procurement terms, see order.
- Identity confirmation by mass spectrometry, verifying the molecular weight matches the intended cyclic peptide.
- Purity by HPLC, reported as a main-peak percentage that flags truncation or byproducts.
- Lot-number traceability, linking the COA to the exact vial in hand.
- Documentation that lets one experiment be compared meaningfully against another.
Regulatory and Compliance Context
Stating the regulatory category plainly is part of responsible science communication. PT-141 supplied here is a research chemical for laboratory and in-vitro use only. It is not a drug, is not a dietary supplement, is not a cosmetic, and is not approved by the FDA for the topics discussed. It is not for human or animal consumption and is not intended for administration to the body in any form.
Because the melanocortin system intersects with topics of human health, any question about sexual health, neurological function, or related concerns belongs with a licensed clinician, never with a research-chemical purchase. Researchers handling PT-141 are responsible for complying with the laws and institutional rules that apply in their jurisdiction. For the broader research category and related answer-first material, see sexual-health peptides and the research questions hub.
Create a free research account to view current pricing and bundles and place an order.
Frequently asked questions
What is PT-141 in a research context?
PT-141, also called bremelanotide, is a cyclic synthetic melanocortin peptide studied as a molecular tool in receptor pharmacology and neuroscience research. In laboratory work it is used to probe how melanocortin receptors, with MC4R a principal interest, respond to a stable agonist. It is a research-use-only reference material, not a drug, supplement, or cosmetic, and it is not for human or animal consumption. It is studied to generate mechanistic data rather than outcomes in people.
What does the name bremelanotide mean?
Bremelanotide is the developmental name used in the scientific and pharmacology literature for the compound commonly labeled PT-141. The two names refer to the same cyclic melanocortin peptide. Researchers may encounter either term when reviewing receptor studies. Regardless of the name used, the material discussed here is a research chemical for laboratory and in-vitro use only, not a product for human or animal consumption, and not FDA approved for the topics described.
Which melanocortin receptors does PT-141 engage?
In cloned-receptor studies, PT-141 is characterized as a melanocortin agonist whose profile includes central subtypes, with MC4R among the receptors of principal interest. The melanocortin family has five subtypes, MC1R through MC5R, all coupling to the Gs pathway and driving cAMP accumulation when activated. Investigators run binding and functional assays across the whole panel to define selectivity. These are in-vitro pharmacology observations that describe receptor behavior, not effects in humans or animals.
How does PT-141 differ from Melanotan II?
Both are cyclic melanocortin analogs in the same stabilized-chemistry lineage, but the research literature distinguishes them by receptor emphasis. Melanotan II is described as a broad, potent agonist across multiple subtypes and is studied heavily in pigment-cell biology, while PT-141 is discussed in connection with central melanocortin signaling and MC4R. Both are referenced only as laboratory research materials, not for human or animal consumption, and not FDA approved.
What does central melanocortin signaling mean?
Central melanocortin signaling refers to melanocortin receptor activity in the brain, especially through MC4R expressed in the hypothalamus and connected regions. In animal models this circuitry integrates various neuroendocrine signals. PT-141 is studied against these central receptors, which distinguishes it from compounds studied mainly for pigment biology or peripheral pathways. This is a research description of receptor location and circuitry in non-human systems, not a statement about any effect in people.
How is PT-141 handled and stored in research?
In laboratory settings, lyophilized PT-141 is typically reconstituted with a suitable sterile solvent, often bacteriostatic or sterile water, added slowly to the vial wall. Sealed vials are usually stored frozen and protected from light and moisture, while reconstituted solutions are kept refrigerated and used within a limited window, avoiding repeated freeze-thaw cycles. These are general research-handling notes for laboratory use only and are not instructions for any use in humans or animals.
Is PT-141 FDA approved or for human use?
No. PT-141 as supplied here is a research chemical for laboratory and in-vitro use only. It is not for human use, animal use, or any form of consumption, and it is not a food, drug, supplement, or cosmetic. It is not FDA approved for the research topics described. Any question about sexual health or neurological function belongs with a licensed clinician. Qualified researchers handling the material must follow all applicable laws and institutional rules.
Why do purity and a COA matter for PT-141?
Receptor data are only as trustworthy as the compound that produced them, and a cyclic peptide can be confounded by truncated sequences, incomplete cyclization, or byproducts. A Certificate of Analysis documents identity by mass spectrometry and purity by HPLC, tied to a lot number that matches the physical vial. That chain of identity lets one experiment be compared meaningfully against another and attributes any finding to the intended molecule rather than an unverified impurity.
All guides · Order research peptides
External references: U.S. Food and Drug Administration · Peptide (Wikipedia)